Baqsimi Európai Unió - magyar - EMA (European Medicines Agency)

baqsimi

eli lilly nederland b.v. - a glukagon - diabetes mellitus - hasnyálmirigy, hormonok, glycogenolytic hormonok - baqsimi kezelésére javallt, a súlyos hypoglykaemia a felnőttek, serdülők, valamint a gyermekek 4 év alatt több mint a diabetes mellitus.

Mounjaro Európai Unió - magyar - EMA (European Medicines Agency)

mounjaro

eli lilly nederland b.v. - tirzepatide - diabetes mellitus, 2. típus - cukorbetegségben szedett gyógyszerek - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5. és 5. sz.

Trulicity Európai Unió - magyar - EMA (European Medicines Agency)

trulicity

eli lilly nederland b.v. - dulaglutide - diabetes mellitus, 2. típus - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. a tanulmányi eredmények tekintetében kombinációk hatása a vércukorcsökkentő, valamint a szív-érrendszeri események, valamint a lakosság tanult, lásd 4. 4, 4. 5. és 5. sz.

Verzenios Európai Unió - magyar - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - mellnövekedés - daganatellenes szerek - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Jaypirca Európai Unió - magyar - EMA (European Medicines Agency)

jaypirca

eli lilly nederland b.v. - pirtobrutinib - lymphoma, mantle-cell - a protein kináz inhibitorok - treatment of mantle cell lymphoma (mcl).

Retsevmo Európai Unió - magyar - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - daganatellenes szerek - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Portrazza Európai Unió - magyar - EMA (European Medicines Agency)

portrazza

eli lilly nederland b.v. - necitumumab - karcinóma, nem kissejtes tüdő - daganatellenes szerek - portrazza gemcitabin és ciszplatin kombinált kemoterápiával kombinálva javallt a felnőtt betegek kezelése helyileg előrehaladott vagy áttétes epidermális növekedési faktor receptor (egfr) kifejező laphám nem-kissejtes tüdőrák ki nem kapott kemoterápiás ebben az állapotban.